FDA Advisory Committee Votes in Favor of the Benefits of Teplizumab Outweighing the Risks in Support of Approval to Delay Clinical Type 1 Diabetes (T1D)
Go back to FDA Advisory Committee Votes in Favor of the Benefits of Teplizumab Outweighing the Risks in Support of Approval to Delay Clinical Type 1 Diabetes (T1D)| Powder River Basin & Gas Corporation (NASDAQ: PRVB) | Delayed: 24.98 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.98 | 52 Week High | $0.17 | |||
| Open | $41.76 | 52 Week Low | $0.17 | |||
| Day High | $24.98 | P/E | 499.60 | |||
| Day Low | $24.98 | EPS | $0.05 | |||
| Volume | 9,073,039 | |||||
